{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:24:52Z","timestamp":1782797092147,"version":"3.54.5"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Antimicrobial resistance is a global health threat, compounded by the reduction in the discovery of new antibiotics. A repurposed drugs-based approach could provide a viable alternative for the treatment of multidrug-resistant (MDR) bacterial infections. In this study, we sought to evaluate the <jats:italic toggle=\"yes\">in vitro<\/jats:italic> efficacy of a novel drug combination, polymyxin B\/trimethoprim (PT) + rifampin on MDR isolates from patients with bacterial keratitis in India.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Forty-three isolates, which included 20 <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>, 19 <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>, <jats:italic toggle=\"yes\">3 Pseudomonas stutzeri<\/jats:italic>, and 1 <jats:italic toggle=\"yes\">Acinetobacter baumannii<\/jats:italic>, were evaluated for their antibiotic resistance by minimum inhibitory concentration (MIC). Fractional Inhibitory Concentration Index (FICI) testing was performed to measure the antimicrobial impact of PT + rifampin in combination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among <jats:italic toggle=\"yes\">S. aureus<\/jats:italic> isolates, 100% were resistant to at least 1 antibiotic class, 12 (60%) were MDR, and 14 (70%) were classified as methicillin-resistant. Among the gram-negative isolates, &gt;90% were classified as MDR. Fractional Inhibitory Concentration (FIC) testing revealed that PT + rifampin was effective in completely inhibiting growth of all isolates while also displaying additive or synergistic activity in approximately 70% of the strains. Mean FICI values were 0.753 \u00b1 0.311 and 0.791 \u00b1 0.369 for <jats:italic toggle=\"yes\">S. aureus<\/jats:italic> and gram-negative isolates, respectively, and a &gt;2-fold reduction in MIC was measured for both PT and rifampin when tested in combination versus alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our data demonstrate the ability of PT + rifampin to eliminate all isolates tested, even those conferring MDR, highlighting the promise of this drug combination for the treatment of bacterial keratitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000003528","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T18:36:53Z","timestamp":1711564613000},"page":"1044-1048","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of a Novel Antibiotic Drug Combination Toward Multidrug-Resistant Ocular Pathogens"],"prefix":"10.1097","volume":"43","author":[{"given":"Lakshminarayanan","family":"Gowtham","sequence":"first","affiliation":[{"name":"Dr Chigurupati Nageswara Rao Ocular Pharmacology Research Centre, LV Prasad Eye Institute, Hyderabad, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A. F.","family":"Wozniak","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology;"},{"name":"Department of Microbiology and Immunology, University of Rochester, Rochester NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Dunman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Rochester, Rochester NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sheba","sequence":"additional","affiliation":[{"name":"Jhaveri Microbiology Centre, LV Prasad Eye Institute, Hyderabad, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Garg","sequence":"additional","affiliation":[{"name":"Shantilal Shanghvi Cornea Institute, LV Prasad Eye Institute, Hyderabad, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-1977","authenticated-orcid":false,"given":"Joveeta","family":"Joseph","sequence":"additional","affiliation":[{"name":"Jhaveri Microbiology Centre, LV Prasad Eye Institute, Hyderabad, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4103\/0301-4738.53051","article-title":"Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade","volume":"57","author":"Gopinathan","year":"2009","journal-title":"Indian J Ophthalmol."},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41433-020-01339-3","article-title":"Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance","volume":"35","author":"Ting","year":"2021","journal-title":"Eye"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jfo.2018.01.012","article-title":"Characterization of virulence factors, antimicrobial resistance patterns and biofilm formation of Pseudomonas aeruginosa and Staphylococcus spp. strains isolated from corneal infection","volume":"41","author":"Heidari","year":"2018","journal-title":"J Fr Ophtalmol."},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"1250257","DOI":"10.3389\/fcimb.2023.1250257","article-title":"Staphylococcus aureus and Pseudomonas aeruginosa infectious keratitis: key bacterial mechanisms that mediate pathogenesis and emerging therapeutics","volume":"13","author":"Shah","year":"2023","journal-title":"Front Cell Infect Microbiol."},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/0301-4738.40360","article-title":"Medical management approach to infectious keratitis","volume":"56","author":"Gokhale","year":"2008","journal-title":"Indian J Ophthalmol."},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/ICO.0000000000000428","article-title":"Trends in microbiological and antibiotic sensitivity patterns in infectious keratitis: 10-year experience in Mexico City","volume":"34","author":"Hernandez-Camarena","year":"2015","journal-title":"Cornea"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/09286586.2013.790978","article-title":"Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India","volume":"20","author":"Oldenburg","year":"2013","journal-title":"Ophthalmic Epidemiol."},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.4103\/ijo.IJO_1033_22","article-title":"Fluoroquinolone resistance in bacterial isolates from ocular infections: trend in antibiotic susceptibility patterns between 2005-2020","volume":"70","author":"Chatterjee","year":"2022","journal-title":"Indian J Ophthalmol."},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/bjophthalmol-2016-308487","article-title":"Trends in antibiotic resistance in bacterial keratitis isolates from South India","volume":"101","author":"Lalitha","year":"2017","journal-title":"Br J Ophthalmol."},{"key":"R10-20250723","first-page":"e01929","article-title":"Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections","volume":"63","author":"Chojnacki","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20250723","first-page":"e00777","article-title":"A novel, broad-spectrum antimicrobial combination for the treatment of Pseudomonas aeruginosa corneal infections","volume":"63","author":"Chojnacki","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/tvst.11.5.26","article-title":"Antimicrobial activity of a triple antibiotic combination toward ocular Pseudomonas aeruginosa clinical isolates","volume":"11","author":"Mei","year":"2022","journal-title":"Transl Vis Sci Technol."},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/ICO.0000000000002414","article-title":"Efficacy of a novel ophthalmic antimicrobial drug combination toward a large panel of Staphylococcus aureus clinical ocular isolates from around the world","volume":"39","author":"Laskey","year":"2020","journal-title":"Cornea"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/bjo.84.1.54","article-title":"Corneal ulceration in the elderly in Hyderabad, south India","volume":"84","author":"Kunimoto","year":"2000","journal-title":"Br J Ophthalmol."},{"key":"R16-20250723","first-page":"746","article-title":"Trimethoprim-polymyxin B ophthalmic solution in treatment of surface ocular bacterial infections","volume":"17","author":"Nozik","year":"1985","journal-title":"Ann Ophthalmol."},{"key":"R17-20250723","first-page":"274","article-title":"Trimethoprim-polymyxin ophthalmic solution versus chloramphenicol ophthalmic solution in the treatment of bacterial conjunctivitis","volume":"3","author":"Van Rensburg","year":"1982","journal-title":"Pharmatherapeutica"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jac\/dkm357","article-title":"Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review","volume":"60","author":"Zavascki","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"R19-20250723","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/j.1875-9114.1981.tb03548.x","article-title":"Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications","volume":"1","author":"Gleckman","year":"1981","journal-title":"Pharmacotherapy"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:03:31Z","timestamp":1753279411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000003528","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"2023-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}